Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino acid peptide derived from the thymus gland, primarily utilized by the community for immune support and as an antiviral adjunct. While clinician-tier protocols often dose 1.6 mg daily, community users frequently report a wider range of 100 µg to 1.6 mg, most commonly settling at 500 µg. Users should be aware that the evidence base for its various exploratory indications remains thin, with many studies lacking posted results or remaining in early stages. Reports of side effects are minimal, with only occasional mentions of sleep changes or injection-site reactions.

Half-life~2 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.52.83.93.53.24.0

Research Evidence

Evidence shape

Thymosin Alpha-1 carries moderate evidence, supported by a single published human study and a broad landscape of 54 registered trials. While the research spans 49 distinct indications—including oncology, sepsis, and viral infections—the vast majority of these trials remain exploratory or exist as single-study, long-tail investigations. Despite the presence of Phase 3-grade trial designs and 12 distinct sponsors, the clinical record is characterized by a significant lack of posted results, leaving most of the therapeutic breadth unverified by completed, public data.

Depthhow much
54 registered trials
22 completed · 1 with posted results · 14 recruiting / active · combined n=189
Breadthhow many areas
49 indications mapped
1 with results · 44 thin / exploratory · 1 animal-only · 41 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
13 distinct sponsors · AE table from NCT04428008 · 25 linked publications on registered trials
Breadth and depth79 rows captured
Human
direct clinical signal
55
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Thymosin Alpha-1 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Lilipeptide
China
500 mg×10
$110.00
$0.22/mg
2
Bio Hack London
GB
100 mg
$87.23
$0.872/mg
3
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
4
Uther
unknown
100 mg×10
$145.00
$1.45/mg
5
High Purity Peptides
Hong Kong
100 mg×10
$150.00
$1.5/mg
6
Mrbeetoe
--
50 mg
$90.00
$1.8/mg

price offers can be sorted by column · 19 out-of-stock offers not shown

1-6 of 206

THYMOSIN ALPHA-1 dosing & protocol

How THYMOSIN ALPHA-1 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 23
Typical dose
1.6 mg1.6 mg – 3.2 mg
typical
0
1 mg
2 mg
3 mg
4 mg
distribution of 10 reported doses · darker = more
Frequency
weekly
Route
subQ

In research trials, thymosin alpha-1 was administered subcutaneously at 1.6 mg once weekly, with doses ranging from 1.6 mg to 3.2 mg per injection.

23 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Typical dose
1.6 mg
typical
0
1 mg
2 mg
3 mg
4 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Among clinician sources, two report 1.6 mg subcutaneously daily and one reports the same amount weekly, with no other dosing variations noted.

3 sources
Anecdotal
Community-reported real-world use · n = 16
Typical dose
500 µg100 µg – 1.6 mg
typical
0
1 mg
2 mg
3 mg
4 mg
distribution of 18 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ

Among 16 community reports, half (8) did not specify a schedule and typically used 500 mcg (range 250 mcg–1.2 mcg); of those with a set cadence, weekly dosing (4 reports) averaged 1.5 mg, daily (3 reports) ~1 mg, twice‑weekly (1) 1.6 mg, and every‑few‑days (1) 500 mcg. No cycling was mentioned.

16 sources

Related peptides

ThymalinLL-37ThymulinVIP